Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes
Abstract Purpose Clonal hematopoiesis (CH) describes the aging-associated expansion of mutant hematopoietic cell populations. In various cohorts, CH has been associated with increased morbidity and mortality from non-hematologic diseases such as cardiovascular disease and infections, including COVID...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Translational Medicine Communications |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41231-023-00155-7 |
| _version_ | 1797452080735059968 |
|---|---|
| author | Cathy Smith Bala B. Burugula Morgan A. Jones Qing Li Jacob O. Kitzman Terrence N. Wong |
| author_facet | Cathy Smith Bala B. Burugula Morgan A. Jones Qing Li Jacob O. Kitzman Terrence N. Wong |
| author_sort | Cathy Smith |
| collection | DOAJ |
| description | Abstract Purpose Clonal hematopoiesis (CH) describes the aging-associated expansion of mutant hematopoietic cell populations. In various cohorts, CH has been associated with increased morbidity and mortality from non-hematologic diseases such as cardiovascular disease and infections, including COVID-19. Comorbidities placing individuals at risk of complications from these disorders, such as diabetes, also increase in prevalence with age and frequently co-exist with CH. How CH interacts with other aging-associated comorbidities to impact human health remains unknown. Methods We assessed the impact of CH on the pre-existing end-organ damage and ultimate clinical outcomes among 242 patients hospitalized with COVID-19 at Michigan Medicine from March to June of 2020. In contrast to most previous studies, these patients skewed older with the majority having multiple comorbidities, which placed them at higher risk for end-organ damage and poor clinical outcomes. Results Overall CH was not significantly associated with increased COVID-19 mortality after controlling for other risk factors, although we did note a borderline-significant association specifically for non-DNMT3A CH mutations. In contrast, we observed a significant association between CH and pre-existing chronic kidney disease (CKD), which was strongest for DNMT3A mutant CH. Conclusions These data suggest that the clinical impact of CH is influenced by the specific gene(s) mutated and is further modified by other comorbidities and clinical risk factors frequently present in the elderly. |
| first_indexed | 2024-03-09T15:02:37Z |
| format | Article |
| id | doaj.art-09b601e593de483ba48725a13164ba92 |
| institution | Directory Open Access Journal |
| issn | 2396-832X |
| language | English |
| last_indexed | 2024-03-09T15:02:37Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Translational Medicine Communications |
| spelling | doaj.art-09b601e593de483ba48725a13164ba922023-11-26T13:47:23ZengBMCTranslational Medicine Communications2396-832X2023-10-01811810.1186/s41231-023-00155-7Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomesCathy Smith0Bala B. Burugula1Morgan A. Jones2Qing Li3Jacob O. Kitzman4Terrence N. Wong5Department of Computational Medicine and Bioinformatics, University of MichiganDepartment of Human Genetics, University of MichiganDepartment of Internal Medicine, University of MichiganDepartment of Internal Medicine, University of MichiganDepartment of Human Genetics, University of MichiganDepartment of Cell and Developmental Biology, University of MichiganAbstract Purpose Clonal hematopoiesis (CH) describes the aging-associated expansion of mutant hematopoietic cell populations. In various cohorts, CH has been associated with increased morbidity and mortality from non-hematologic diseases such as cardiovascular disease and infections, including COVID-19. Comorbidities placing individuals at risk of complications from these disorders, such as diabetes, also increase in prevalence with age and frequently co-exist with CH. How CH interacts with other aging-associated comorbidities to impact human health remains unknown. Methods We assessed the impact of CH on the pre-existing end-organ damage and ultimate clinical outcomes among 242 patients hospitalized with COVID-19 at Michigan Medicine from March to June of 2020. In contrast to most previous studies, these patients skewed older with the majority having multiple comorbidities, which placed them at higher risk for end-organ damage and poor clinical outcomes. Results Overall CH was not significantly associated with increased COVID-19 mortality after controlling for other risk factors, although we did note a borderline-significant association specifically for non-DNMT3A CH mutations. In contrast, we observed a significant association between CH and pre-existing chronic kidney disease (CKD), which was strongest for DNMT3A mutant CH. Conclusions These data suggest that the clinical impact of CH is influenced by the specific gene(s) mutated and is further modified by other comorbidities and clinical risk factors frequently present in the elderly.https://doi.org/10.1186/s41231-023-00155-7Clonal hematopoiesisCOVID-19Chronic kidney disease |
| spellingShingle | Cathy Smith Bala B. Burugula Morgan A. Jones Qing Li Jacob O. Kitzman Terrence N. Wong Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes Translational Medicine Communications Clonal hematopoiesis COVID-19 Chronic kidney disease |
| title | Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes |
| title_full | Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes |
| title_fullStr | Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes |
| title_full_unstemmed | Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes |
| title_short | Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes |
| title_sort | impact of clonal hematopoiesis in covid 19 patients at high risk for adverse clinical outcomes |
| topic | Clonal hematopoiesis COVID-19 Chronic kidney disease |
| url | https://doi.org/10.1186/s41231-023-00155-7 |
| work_keys_str_mv | AT cathysmith impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes AT balabburugula impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes AT morganajones impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes AT qingli impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes AT jacobokitzman impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes AT terrencenwong impactofclonalhematopoiesisincovid19patientsathighriskforadverseclinicaloutcomes |